|
JP2791732B2
(ja)
*
|
1992-04-02 |
1998-08-27 |
小野薬品工業株式会社 |
３′−アミノ−２′−ヒドロキシアセトフェノンの製造方法
|
|
US6143749A
(en)
|
1995-06-07 |
2000-11-07 |
Abbott Laboratories |
Heterocyclic substituted cyclopentane compounds
|
|
JP2005527502A
(ja)
|
2002-02-19 |
2005-09-15 |
シーブイ・セラピューティクス・インコーポレイテッド |
Ａ１アデノシン受容体の部分的および全アゴニスト
|
|
US20040043959A1
(en)
|
2002-03-04 |
2004-03-04 |
Bloom Laura A. |
Combination therapies for treating methylthioadenosine phosphorylase deficient cells
|
|
US20040138238A1
(en)
|
2002-08-08 |
2004-07-15 |
Dhanoa Dale S. |
Substituted aminopyrimidine compounds as neurokinin antagonists
|
|
JP4660199B2
(ja)
|
2002-12-23 |
2011-03-30 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
置換１−ピペリジン−４−イル−４−アゼチジン−３−イル−ピペラジン誘導体およびそれらのニューロキニン拮抗薬としての使用
|
|
US7612078B2
(en)
|
2003-03-31 |
2009-11-03 |
Epix Delaware, Inc. |
Piperidinylamino-thieno[2,3-D] pyrimidine compounds
|
|
WO2005110410A2
(en)
|
2004-05-14 |
2005-11-24 |
Abbott Laboratories |
Kinase inhibitors as therapeutic agents
|
|
EP1856128A4
(en)
|
2005-01-19 |
2009-12-23 |
Merck & Co Inc |
INHIBITORS OF MITOTIC KINESINE
|
|
GB0713602D0
(en)
|
2007-07-12 |
2007-08-22 |
Syngenta Participations Ag |
Chemical compounds
|
|
TWI389913B
(zh)
|
2008-09-08 |
2013-03-21 |
Lg Life Sciences Ltd |
并合雜環化合物
|
|
WO2010041366A1
(ja)
|
2008-10-06 |
2010-04-15 |
日本電気株式会社 |
無線通信装置、無線通信システム、無線通信装置の制御方法、及び記録媒体
|
|
WO2010066629A2
(en)
|
2008-12-09 |
2010-06-17 |
F. Hoffmann-La Roche Ag |
Novel azaindoles
|
|
JP2011026305A
(ja)
|
2009-06-24 |
2011-02-10 |
Daiichi Sankyo Co Ltd |
イミダゾールカルボニル化合物を含有する医薬組成物
|
|
WO2011020567A1
(de)
|
2009-08-20 |
2011-02-24 |
Bayer Cropscience Ag |
3-triazolylphenyl-substituierte sulfid-derivate als akarizide und insektizide
|
|
CN102984941B
(zh)
|
2009-09-04 |
2016-08-17 |
密执安大学评议会 |
用于治疗白血病的组合物和方法
|
|
GB201004200D0
(en)
*
|
2010-03-15 |
2010-04-28 |
Univ Basel |
Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
|
|
US9586961B2
(en)
|
2010-07-09 |
2017-03-07 |
Leo Pharma A/S |
Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
|
|
US9145438B2
(en)
|
2010-12-03 |
2015-09-29 |
Epizyme, Inc. |
7-deazapurine modulators of histone methyltransferase, and methods of use thereof
|
|
EP2646455A4
(en)
|
2010-12-03 |
2014-04-02 |
Epizyme Inc |
Modulators of histone methyltransferase, and methods of use thereof
|
|
GB201021623D0
(en)
|
2010-12-21 |
2011-02-02 |
Isis Innovation |
Detection of acute myeloid leukaemia
|
|
EP2736901A1
(en)
|
2011-07-28 |
2014-06-04 |
Cellzome Limited |
Heterocyclyl pyrimidine analogues as jak inhibitors
|
|
CN103228195B
(zh)
|
2011-08-01 |
2016-01-20 |
奥林巴斯株式会社 |
插入部形状估计装置
|
|
IN2014DN01883A
(enExample)
|
2011-09-14 |
2015-05-15 |
Proximagen Ltd |
|
|
WO2014035140A2
(en)
|
2012-08-30 |
2014-03-06 |
Kainos Medicine, Inc. |
Compounds and compositions for modulating histone methyltransferase activity
|
|
CN103664991B
(zh)
|
2012-09-19 |
2016-12-28 |
中国科学院福建物质结构研究所 |
噻吩[2,3‑d]嘧啶衍生物、其制备方法及其用途
|
|
BR112015011148A8
(pt)
|
2012-11-16 |
2019-10-01 |
Merck Sharp & Dohme |
composto, composição farmacêutica, e combinação
|
|
CA2894126A1
(en)
|
2012-12-21 |
2014-06-26 |
Epizyme, Inc. |
Prmt5 inhibitors and uses thereof
|
|
DK2935222T3
(en)
|
2012-12-21 |
2019-01-07 |
Epizyme Inc |
PRMT5 INHIBITORS AND APPLICATIONS THEREOF
|
|
US9745291B2
(en)
|
2012-12-21 |
2017-08-29 |
Epizyme, Inc. |
PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
|
|
WO2014164543A1
(en)
|
2013-03-13 |
2014-10-09 |
The Regents Of The University Of Michigan |
Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
|
|
BR112016008632A8
(pt)
|
2013-10-21 |
2020-03-17 |
Merck Patent Gmbh |
compostos de heteroarila como inibidores de btk, seus usos, e composição farmacêutica
|
|
WO2015171738A2
(en)
|
2014-05-06 |
2015-11-12 |
The Procter & Gamble Company |
Fragrance compositions
|
|
US20170119769A1
(en)
|
2014-06-10 |
2017-05-04 |
The Trustees Of The University Of Pennsylvania |
Scaffolds for inhibitors of menin-mll interactions
|
|
US20170198006A1
(en)
|
2014-06-25 |
2017-07-13 |
Epizyme, Inc. |
Prmt5 inhibitors and uses thereof
|
|
CN105330698B
(zh)
|
2014-07-04 |
2019-05-28 |
齐鲁制药有限公司 |
螺环芳基磷氧化物和硫化物
|
|
JP6487527B2
(ja)
|
2014-07-04 |
2019-03-20 |
チル ファーマシューティカル カンパニー リミテッド |
スピロ環アリールリン酸化物及びアリールリン硫化物（ｓｐｉｒｏｃｙｃｌｉｃ ａｒｙｌ ｐｈｏｓｐｈｏｒｕｓ ｏｘｉｄｅ ａｎｄ ａｒｙｌ ｐｈｏｓｐｈｏｒｕｓ ｓｕｌｆｉｄｅ）
|
|
USRE49687E1
(en)
|
2014-09-09 |
2023-10-10 |
The Regents Of The University Of Michigan |
Thienopyrimidine and thienopyridine compounds and methods of use thereof
|
|
GB201416352D0
(en)
*
|
2014-09-16 |
2014-10-29 |
Shire Internat Gmbh |
Spirocyclic derivatives
|
|
EP3207030A4
(en)
*
|
2014-10-14 |
2018-06-06 |
Merck Sharp & Dohme Corp. |
Inhibitors of the renal outer medullary potassium channel
|
|
WO2016081732A1
(en)
|
2014-11-19 |
2016-05-26 |
Memorial Sloan-Kettering Cancer Center |
Thienopyrimidines and uses thereof
|
|
TN2017000080A1
(en)
|
2014-12-18 |
2018-07-04 |
Takeda Pharmaceuticals Co |
Solid state forms of fused heteroaromatic pyrrolidinones
|
|
CN105732636B
(zh)
|
2014-12-30 |
2020-04-21 |
广东东阳光药业有限公司 |
杂芳化合物及其在药物中的应用
|
|
MX2017010844A
(es)
|
2015-02-24 |
2017-12-07 |
Pfizer |
Derivados de nucleosidos sustituidos utiles como agentes anticancerosos.
|
|
HK1246593A1
(zh)
|
2015-06-04 |
2018-09-14 |
Kura Oncology, Inc. |
用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
|
|
TWI703150B
(zh)
|
2015-06-04 |
2020-09-01 |
美商庫拉腫瘤技術股份有限公司 |
用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
|
|
TWI870767B
(zh)
|
2015-08-26 |
2025-01-21 |
比利時商健生藥品公司 |
使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
|
|
AU2016378579A1
(en)
|
2015-12-22 |
2018-06-14 |
Vitae Pharmaceuticals, Inc. |
Inhibitors of the menin-MLL interaction
|
|
US10869868B2
(en)
|
2016-01-26 |
2020-12-22 |
Memorial Sloan Kettering Cancer Center |
Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia
|
|
PH12018501955B1
(en)
|
2016-03-16 |
2024-01-24 |
Kura Oncology Inc |
Bridged bicyclic inhibitors of menin-mll and methods of use
|
|
PL3429591T3
(pl)
|
2016-03-16 |
2023-07-17 |
Kura Oncology, Inc. |
Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania
|
|
JP6991585B2
(ja)
|
2016-05-02 |
2022-01-12 |
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン |
メニン阻害剤としてのピペリジン
|
|
WO2017207387A1
(en)
|
2016-05-31 |
2017-12-07 |
Bayer Pharma Aktiengesellschaft |
Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
|
|
WO2017214367A1
(en)
|
2016-06-10 |
2017-12-14 |
Vitae Pharmaceuticals, Inc. |
Inhibitors of the menin-mll interaction
|
|
WO2018024602A1
(en)
|
2016-08-04 |
2018-02-08 |
Bayer Aktiengesellschaft |
2,7-diazaspiro[4.4]nonanes
|
|
WO2018047598A1
(ja)
|
2016-09-06 |
2018-03-15 |
株式会社スリーボンド |
熱硬化型導電性接着剤
|
|
EP3512857B1
(en)
|
2016-09-14 |
2021-02-24 |
Janssen Pharmaceutica NV |
Spiro bicyclic inhibitors of menin-mll interaction
|
|
CA3033020A1
(en)
|
2016-09-14 |
2018-03-22 |
Janssen Pharmaceutica Nv |
Fused bicyclic inhibitors of menin-mll interaction
|
|
CA3033239A1
(en)
|
2016-09-14 |
2018-03-22 |
Janssen Pharmaceutica Nv |
Spiro bicyclic inhibitors of menin-mll interaction
|
|
US12084462B2
(en)
|
2016-09-14 |
2024-09-10 |
Janssen Pharmaceutica Nv |
Spiro bicyclic inhibitors of menin-MLL interaction
|
|
AU2017326006B2
(en)
|
2016-09-16 |
2021-10-28 |
Vitae Pharmaceuticals, LLC. |
Inhibitors of the menin-MLL interaction
|
|
WO2018106820A1
(en)
|
2016-12-07 |
2018-06-14 |
Kura Oncology, Inc. |
Methods of promoting beta cell proliferation
|
|
WO2018106818A1
(en)
|
2016-12-07 |
2018-06-14 |
Kura Oncology, Inc. |
Methods of promoting beta cell proliferation
|
|
WO2018109088A1
(en)
|
2016-12-15 |
2018-06-21 |
Janssen Pharmaceutica Nv |
Azepane inhibitors of menin-mll interaction
|
|
CN110248946B
(zh)
|
2016-12-15 |
2023-05-23 |
詹森药业有限公司 |
Menin-MLL相互作用的氮杂环庚烷抑制剂
|
|
CN108456208B
(zh)
|
2017-02-22 |
2021-04-16 |
广州市恒诺康医药科技有限公司 |
氮杂螺环类化合物及其制备方法和应用
|
|
WO2018175746A1
(en)
|
2017-03-24 |
2018-09-27 |
Kura Oncology, Inc. |
Methods for treating hematological malignancies and ewing's sarcoma
|
|
WO2018226976A1
(en)
|
2017-06-08 |
2018-12-13 |
Kura Oncology, Inc. |
Methods and compositions for inhibiting the interaction of menin with mll proteins
|
|
TW201904577A
(zh)
|
2017-06-16 |
2019-02-01 |
美商貝達醫藥公司 |
N-(2-(2-二甲胺基)乙氧基)-4-甲氧基-5-((4-(1-甲基-1h-吲哚-3-基)嘧啶-2-基)胺基)苯基)丙烯醯胺及其鹽之醫藥調配物
|
|
CA3069558A1
(en)
|
2017-07-09 |
2019-01-17 |
Biosight Ltd. |
Combination cancer therapy
|
|
EP3684361A4
(en)
*
|
2017-09-20 |
2021-09-08 |
Kura Oncology, Inc. |
SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHOD OF USING
|
|
GB201720077D0
(en)
|
2017-12-01 |
2018-01-17 |
Univ Oxford Innovation Ltd |
Leukaemic stem cell
|
|
US11396517B1
(en)
|
2017-12-20 |
2022-07-26 |
Janssen Pharmaceutica Nv |
Exo-aza spiro inhibitors of menin-MLL interaction
|
|
JP7307729B2
(ja)
|
2017-12-20 |
2023-07-12 |
ヤンセン ファーマシューティカ エヌ．ベー． |
メニン－ｍｌｌ相互作用のエキソ－アザスピロ阻害剤
|
|
KR102779601B1
(ko)
|
2018-08-27 |
2025-03-12 |
스미토모 파마 가부시키가이샤 |
광학 활성인 아자비시클로환 유도체
|
|
JP2022503792A
(ja)
|
2018-09-26 |
2022-01-12 |
クラ オンコロジー，インク． |
メニン阻害剤を用いた血液悪性腫瘍の処置
|
|
IL283755B2
(en)
|
2018-12-07 |
2026-04-01 |
Univ Maryland |
N-(Phenyl-4-methylamino)-5-naphthalene-1-sulfonamide compounds and pharmaceutical preparations containing them
|
|
TW202104207A
(zh)
|
2019-04-17 |
2021-02-01 |
美商健生生物科技公司 |
二氫乳清酸脫氫酶抑制劑
|
|
US12595252B2
(en)
|
2019-06-14 |
2026-04-07 |
Disarm Therapeutics, Inc. |
Inhibitors of SARM1
|
|
KR102924600B1
(ko)
|
2019-12-18 |
2026-02-09 |
솔루스첨단소재 주식회사 |
유기 화합물 및 이를 이용한 유기 전계 발광 소자
|
|
TW202525813A
(zh)
|
2019-12-19 |
2025-07-01 |
比利時商健生藥品公司 |
經取代之直鏈螺環接衍生物
|
|
CN111297863B
(zh)
|
2020-03-30 |
2021-06-25 |
四川大学华西医院 |
menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
|
|
EP4132932A4
(en)
|
2020-04-07 |
2024-04-17 |
Syndax Pharmaceuticals, Inc. |
COMBINATIONS OF MENIN INHIBITORS AND CYP3A4 INHIBITORS AND METHODS OF USE THEREOF
|
|
CR20230415A
(es)
|
2020-11-30 |
2023-09-08 |
Kotobuki Pharmaceutical Co Ltd |
Compuesto de heteroarilcarboxamida
|
|
US20240417405A1
(en)
|
2021-05-08 |
2024-12-19 |
Janssen Pharmaceutica Nv |
Substituted Spiro Derivatives
|
|
CA3215379A1
(en)
|
2021-05-08 |
2022-11-17 |
Olivier Alexis Georges Querolle |
Substituted spiro derivatives
|
|
PE20240588A1
(es)
|
2021-05-11 |
2024-03-21 |
Janssen Pharmaceutica Nv |
Terapias de combinacion
|
|
MX2023013410A
(es)
|
2021-05-11 |
2023-12-06 |
Janssen Pharmaceutica Nv |
Terapias de combinacion.
|
|
US20240238291A1
(en)
|
2021-05-12 |
2024-07-18 |
Syndax Pharmaceuticals, Inc. |
Combinations for treatment of cancer
|
|
IL308862A
(en)
|
2021-06-01 |
2024-01-01 |
Janssen Pharmaceutica Nv |
Altered phenyl-1H-pyrrolo[3,2-c]pyridine histories
|
|
JP2024521902A
(ja)
|
2021-06-03 |
2024-06-04 |
ヤンセン ファーマシューティカ エヌ．ベー． |
スピロ環状アミンで置換されたピリダジン又は１，２，４－トリアジン
|
|
WO2022262796A1
(en)
|
2021-06-17 |
2022-12-22 |
Janssen Pharmaceutica Nv |
(r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-m ethylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer
|
|
IL313033A
(en)
*
|
2021-12-03 |
2024-07-01 |
Bionova Pharmaceuticals Shanghai Ltd |
Carbonyl substituted diazaspiro compounds and its use
|
|
CN118234497A
(zh)
|
2021-12-15 |
2024-06-21 |
丹娜-法伯癌症研究所 |
通过破坏menin-mll表观遗传复合体靶向治疗胃肠道间质瘤(gist)
|
|
US20250152591A1
(en)
*
|
2022-02-04 |
2025-05-15 |
Kura Oncology, Inc. |
Treatment of hematological malignancies with menin inhibitors and p-glycoprotein inhibitors
|
|
US20250295661A1
(en)
|
2022-05-09 |
2025-09-25 |
Syndax Pharmaceuticals, Inc. |
Menin-mll inhibitors for the treatment of cancer
|
|
EP4626426A1
(en)
|
2022-11-30 |
2025-10-08 |
JANSSEN Pharmaceutica NV |
Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent
|
|
CN120359221A
(zh)
|
2022-11-30 |
2025-07-22 |
詹森药业有限公司 |
环丁基取代的双环化合物
|
|
WO2024114666A1
(en)
|
2022-11-30 |
2024-06-06 |
Janssen Pharmaceutica Nv |
Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor
|
|
JP2025541695A
(ja)
|
2022-11-30 |
2025-12-23 |
ヤンセン ファーマシューティカ エヌ．ベー． |
置換１－フェニル－３，４－ジヒドロピリド［３，４－ｄ］ピリミジン－２－オン誘導体
|
|
EP4698182A1
(en)
|
2023-04-17 |
2026-02-25 |
Janssen Pharmaceutica NV |
Combination of a menin-ll1 inhibitor, a dna intercalating agent and a pyrimidine analogue to treat a hematopoietic disorder
|